Compare Incyte Corporation (INCY) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Ltd. — how do they compare? Incyte Corporation trades at $115.81 (market cap $23.44B), while Invesco Ltd. trades at $30.5 (market cap $13.34B). The key difference: Incyte Corporation is the larger of the two by market cap, and Invesco Ltd. pays a 2.86% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | IVZ | |
|---|---|---|
Market Cap | $23.44B | $13.34B |
Sector | Health | Financials |
52-Week High | $118.52 | $30.30 |
52-Week Low | $68.90 | $20.45 |
Enterprise Value | $19.46B | $23.59B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Invesco (IVZ) trades at $30.10, up 1.59% with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 earnings, missing estimates after two consecutive beats. While revenue has grown to $6.38 billion in 2025, net income remains negative at -$281.7 million, though improving from 2023 lows. Analyst consensus shows 42.9% buy ratings with a $30.64 price target, slightly above current levels.
IVZ presents a balanced risk-reward profile with improving operational cash flow ($1.53B in 2025) and positive earnings momentum offset by persistent negative profitability metrics. The stock's valuation appears reasonable with P/E of 19.48 and P/B of 1.35, but investors face execution risks amid competitive asset management pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
